SEC Filing Analysis: Denali Therapeutics Inc. (DNLI)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director received a standard equity compensation package, including Restricted Stock Units (RSUs) and stock options, as part of their role. The transaction is not an open-market trade and has negligible market impact.
• Market Impact: Neutral. This is a routine grant with minimal dilution.

Company Information

Field	Value
Company	Denali Therapeutics Inc.
Ticker Symbol	DNLI
CIK	0001714899
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Van Hauwermeiren Timothy
CIK	0001816206
Title/Position	null
Relationship	Director

Transaction Details

This filing reports two grants: one for RSUs and one for stock options. The details below are for the RSU grant.

Field	Value
Form Type	4
Transaction Date	2025-11-04
Transaction Code	A (Grant)
Security Type	Common Stock (as RSUs)
Shares Involved	10,632
Price Per Share	$0.00
Total Value	$0
Shares Owned After	10,632 (unvested RSUs)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.0%
Shares Transacted (RSUs + Options)	42,529
% of Shares Outstanding	0.029%
Post-Transaction Ownership (RSUs)	10,632 shares (0.007% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The grant's value is non-cash compensation. For a company with a $2.25 billion market cap, this equity award is a standard part of director compensation and not financially material to the company's valuation.
• Dilution Impact: The combined grant of 10,632 RSUs and 31,897 stock options represents a potential dilution of only 0.029% of total shares outstanding. This is a negligible impact on existing shareholders.
• Transaction Significance: The transaction is categorized as 'Low' significance because it is a compensatory grant, not an open-market purchase, and its size relative to both market cap and shares outstanding is minimal.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity grants to directors are routine and expected forms of compensation. They do not signal new insider sentiment based on market conditions and are not indicative of a future stock price movement.

Volume & Sentiment

• Expected Volume Impact: None. This is not an open-market transaction and will not directly impact trading volume.
• Sentiment Indicator: Neutral. The market generally views such compensation as a standard cost of business for public companies.

Additional Context

Transaction Notes

• Vesting Schedule: The 10,632 RSUs vest in four equal annual installments. The 31,897 stock options have a one-year cliff, vesting 25% on the first anniversary, with the remainder vesting monthly over the following three years. This long-term vesting schedule aligns the director's interests with those of shareholders.